ROS1 and cancer: At the time we submitted this paper, no drug had proven to overcome G2032R-mutated ROS1 fusion in clinic, but while our paper reviewed, it was reported TPX-0005 (Repotrectinib) showed activity against ROS1-G2032R mutation positive cancer patient in phase 1/2 clinical trial.